Welcome to our dedicated page for Dyne Therapeutics news (Ticker: DYN), a resource for investors and traders seeking the latest updates and insights on Dyne Therapeutics stock.
Dyne Therapeutics, Inc. (Nasdaq: DYN) is a pioneering biotechnology company based in Waltham, Massachusetts, that is dedicated to developing therapeutic solutions for genetically driven muscle diseases. Founded in 2017, Dyne Therapeutics leverages its proprietary FORCE™ platform to overcome the delivery challenges associated with modern oligonucleotide therapeutics, aiming to provide life-transforming treatments for patients.
Dyne's primary focus is on advancing therapeutics for muscle disorders such as Myotonic Dystrophy Type 1 (DM1), Duchenne Muscular Dystrophy (DMD), and Facioscapulohumeral Muscular Dystrophy (FSHD). The company’s lead programs include DYNE-101 for DM1 and DYNE-251 for DMD, both of which have shown promising clinical results. Recent clinical trials have demonstrated dose-dependent splicing correction, improvement in muscle strength, and favorable safety profiles.
In January 2024, Dyne announced the successful completion of a $345 million public offering, extending its cash runway through 2025. This funding enables the company to advance its clinical programs and pursue expedited regulatory pathways to bring its therapies to market more swiftly.
Dyne’s recent milestones include:
- Positive clinical data from the Phase 1/2 ACHIEVE trial of DYNE-101 in DM1 patients, showing dose-dependent muscle delivery and splicing correction.
- Meaningful improvement in functional endpoints and dystrophin expression in the Phase 1/2 DELIVER trial of DYNE-251 in DMD patients.
- Ongoing efforts to enhance dosing regimens and seek accelerated approval pathways with global regulatory authorities.
With a robust pipeline and a dedicated team, Dyne is committed to addressing the unmet needs of patients with rare muscle diseases, aiming to transform their treatment landscape and improve their quality of life.
Dyne Therapeutics has submitted an Investigational New Drug (IND) application for DYNE-251, targeting Duchenne muscular dystrophy (DMD) patients with mutations suitable for exon 51 skipping. This marks a significant milestone for the company, which aims to initiate patient dosing in clinical trials by mid-2022. The upcoming Phase 1/2 trial plans to enroll 30-40 patients aged 4 to 16, focusing on safety and efficacy metrics. In addition to DYNE-251, Dyne is also developing treatments targeting other DMD-related mutations.
Dyne Therapeutics (Nasdaq: DYN) announced advancements in its leading therapeutic candidates during Q3 2021, with IND submissions for DYNE-251 in DMD expected in Q4 2021 and DYNE-101 in DM1 anticipated in Q1 2022. Recent in vivo data demonstrated significant dystrophin restoration and toxic RNA knockdown. Despite a net loss of $42.6 million for Q3, the company holds $407.5 million in cash, funding operations into mid-2024. Upcoming investor events will further highlight its commitment to developing transformative therapies for genetically driven muscle diseases.
Dyne Therapeutics (DYN) held its inaugural Research and Development Day, announcing the planned submissions of Investigational New Drug (IND) applications for DYNE-251 in Duchenne muscular dystrophy (DMD) by Q4 2021 and DYNE-101 in myotonic dystrophy type 1 (DM1) by Q1 2022. The event featured expert commentary from Dr. Valeria Sansone and Dr. John Day, highlighting the urgency of advancing therapies for these underserved conditions. The company is also preparing to submit an IND for DYNE-301 in facioscapulohumeral muscular dystrophy (FSHD) in H2 2022.
Dyne Therapeutics announced significant findings at the 2021 Muscle Study Group meeting, showcasing the effectiveness of DYNE-251 in treating Duchenne muscular dystrophy (DMD). In mdx mouse models, a single dose achieved 90% dystrophin restoration in the diaphragm and 78% in the heart, with over 80% dystrophin-positive fibers. In non-human primates, DYNE-251 demonstrated 52% and 43% exon 51 skipping in the diaphragm and heart, respectively. The platform, FORCE™, shows potential for less frequent dosing compared to current therapies, aiming to advance to clinical studies.
Dyne Therapeutics (Nasdaq: DYN) is hosting a virtual Research and Development Day on October 13, 2021, from 8:00 – 10:30 a.m. ET. The event, titled “The Muscle to Move to the Clinic”, will showcase preclinical data for the company’s programs targeting myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD). Leading experts, including Dr. Valeria Sansone and Dr. John Day, will present updates and discuss advancing these programs into clinical trials. A live webcast will be available with a replay for 90 days.
Dyne Therapeutics, focused on innovative therapies for muscle diseases, announced its participation in Chardan’s Virtual 5th Annual Genetic Medicines Conference. Management, including CEO Joshua Brumm and CSO Oxana Beskrovnaya, will engage in a fireside chat on October 5, 2021, at 9:00 a.m. ET. The event will feature a live webcast available on Dyne's website, with replay access for 90 days. Dr. Beskrovnaya will also speak in a panel on RNA-based delivery approaches. The company is advancing therapeutics for conditions like Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1).
Dyne Therapeutics announced new in vivo data regarding its DM1 candidate, DYNE-101, at the WMS 2021 Virtual Congress. The data demonstrated a 49% reduction in toxic human nuclear DMPK RNA in heart tissue, showing potential for disease modification. DYNE-101's mechanism involves targeting toxic RNA, allowing normal splicing and protein function. The program is part of Dyne's broader strategy, with three IND submissions planned between Q4 2021 and Q4 2022. The company emphasizes the safety of DYNE-101, with no toxicity observed in non-human primates.
Dyne Therapeutics (DYN) reported its Q2 2021 financial results, highlighting significant advancements in its programs targeting myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral muscular dystrophy (FSHD). The company plans to submit Investigational New Drug applications for all three programs between Q4 2021 and Q4 2022. Financially, Dyne's cash position was $435.6 million, expected to fund operations into H2 2024. R&D expenses surged to $23.9 million, while the net loss widened to $30 million, or $0.58 per share.
Dyne Therapeutics (DYN) recently showcased preclinical data from its FSHD program at the Annual FSHD Society Congress, highlighting the efficacy of its FORCE™ platform. The lead FSHD candidate demonstrated significant suppression of DUX4 biomarkers in an FSHD patient cell line. This approach targets the genetic underpinnings of FSHD, a progressive muscular dystrophy with no approved treatments. Dyne plans to submit three IND applications between Q4 2021 and Q4 2022 as it advances its innovative therapies, aimed at addressing the critical need for effective treatments for this debilitating condition.
Dyne Therapeutics announced the resignation of co-founder Romesh Subramanian, who will transition to an advisory role after successfully leading R&D efforts. Oxana Beskrovnaya has been appointed as the new Chief Scientific Officer. The company is focused on advancing innovative therapeutics for genetically driven muscle diseases. Under Subramanian's leadership, Dyne established its pipeline, which is nearing clinical trials. Beskrovnaya aims to continue this momentum and enhance Dyne's scientific capabilities.
FAQ
What is the current stock price of Dyne Therapeutics (DYN)?
What is the market cap of Dyne Therapeutics (DYN)?
What does Dyne Therapeutics, Inc. specialize in?
What are the main diseases Dyne Therapeutics targets?
What is DYNE-101?
What is DYNE-251?
How is Dyne Therapeutics funded for their projects?
Where is Dyne Therapeutics headquartered?
When was Dyne Therapeutics founded?
What recent achievements has Dyne Therapeutics made?
What is the FORCE™ platform?
Who are the key investors and partners in Dyne Therapeutics?
